secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001232524-26-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25
--------------------------------------------------------------------------------

- Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.
- Xywav net product sales $408M (+18% YoY) with 425 net patient adds; Epidiolex grew 15% YoY.
- Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review; PDUFA date Aug 25, 2026.
- Company reaffirms 2026 revenue and expense guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/0001232524-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/jazz-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001232524-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer